SCHEMBL33972

SCHEMBL33972

N=C(N)NCCS(=O)(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 2/20 0.50
SMN1; SMN2 Q16637 3/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
KMT2A Q03164 1/20 0.41
BLM P54132 3/20 0.40
LMNA P02545 3/20 0.40
CYP2C19 P33261 2/20 0.40
SLC6A6 P31641 1/20 0.40
APP P05067 1/20 0.37
CYP2D6 P10635 2/20 0.36
PTGS1 P23219 1/20 0.35
PDE4A P27815 1/20 0.35
HIF1A Q16665 2/20 0.34
TSHR P16473 1/20 0.34
KDM4E B2RXH2 2/20 0.32
NPSR1 Q6W5P4 1/20 0.32
ALDH1A1 P00352 2/20 0.30
POLB P06746 2/20 0.30
RAB9A P51151 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28685473 1.00 ALOX15 (0.50) ALOX15SMN1; SMN2MEN1CYP1A2KMT2A
Taurine SCHEMBL25373994 0.92 LMNA (0.56) ALOX15SMN1; SMN2MEN1CYP1A2KMT2A
SCHEMBL4100132 0.86 ALOX15 (0.56) ALOX15SMN1; SMN2MEN1CYP1A2KMT2A
SCHEMBL1561614 0.86 ALOX15 (0.56) ALOX15SMN1; SMN2MEN1CYP1A2KMT2A
SCHEMBL4094270 0.85 ALOX15 (0.55) ALOX15SMN1; SMN2MEN1CYP1A2KMT2A
SCHEMBL11773616 0.85 ALOX15 (0.55) ALOX15SMN1; SMN2MEN1CYP1A2KMT2A
SCHEMBL11773387 0.85 ALOX15 (0.55) ALOX15SMN1; SMN2MEN1CYP1A2KMT2A
SCHEMBL4105263 0.85 ALOX15 (0.55) ALOX15SMN1; SMN2MEN1CYP1A2KMT2A
SCHEMBL11770651 0.85 ALOX15 (0.55) ALOX15SMN1; SMN2MEN1CYP1A2KMT2A
SCHEMBL17234459 0.83 ALOX15 (0.37) ALOX15BLMLMNACYP2C19SLC6A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1092 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12292445-B2 Methods of selecting subjects for treatment with metabolomic modulators THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-05-06 US claimed
WO-2024254556-A9 BACTERIAL COMPOSITIONS FOR METABOLIZING UREMIC TOXINS ATOSSA THERAPEUTICS, INC. (US) 2025-01-30 WO claimed
CN-119384205-A Preparation methods of amidino taurine applied to perovskite active layer and perovskite solar cell module 浙江机电职业技术大学 2025-01-28 CN claimed
CN-119192036-A Synthesis method of amidino taurine 苏州华道生物药业股份有限公司 2024-12-27 CN claimed
WO-2024254556-A1 BACTERIAL COMPOSITIONS FOR METABOLIZING UREMIC TOXINS ATOSSA THERAPEUTICS, INC. (US) 2024-12-12 WO claimed
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 CN claimed
CN-114350331-B Strong-adsorption salt-resistant plugging agent based on nano-silica and water-based drilling fluid 西南石油大学 2023-01-31 CN claimed
CN-114113573-B Biomarker for early prediction of cardiovascular disease (CVD) of diabetic patient and application thereof 中国医学科学院阜外医院 2022-11-11 CN claimed
CN-114350331-A Strong-adsorption salt-resistant plugging agent based on nano-silica and water-based drilling fluid 西南石油大学 2022-04-15 CN claimed
CN-114113573-A Biomarker for early prediction of cardiovascular disease (CVD) of diabetic patient and application thereof 中国医学科学院阜外医院 2022-03-01 CN claimed
US-20130011364-A1 MOLECULARLY IMPRINTED POLYMERS FOR ELIMINATING METABOLITES FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH (DE) 2013-01-10 US claimed
CN-102649772-A Artificially-synthesized taurocyamine and synthetic method thereof NINGXIA XINGPING FINE CHEMICAL STOCK CO LTD 2012-08-29 CN claimed
EP-2091513-B1 EJECTION LIQUID AND EJECTION METHOD CANON KK (JP) 2011-04-06 EP claimed
US-20100116691-A1 BIOSENSOR FOR CONTINUOUS MONITORING OF METABOLITES AND PROTEINS AND METHODS OF MANUFACTURE THEREOF UNIVERSITY OF CONNECTICUT (US) 2010-05-13 US claimed
US-20100069290-A1 EJECTION LIQUID AND EJECTION METHOD CANON KABUSHIKI KAISHA (JP) 2010-03-18 US claimed
EP-2091513-A2 EJECTION LIQUID AND EJECTION METHOD Canon Kabushiki Kaisha (JP) 2009-08-26 EP claimed
WO-2008069012-A2 EJECTION LIQUID AND EJECTION METHOD CANON KABUSHIKI KAISHA (JP) 2008-06-12 WO claimed
CN-1271403-C Polysaccharide quantitative detecting method and system SHANGHAI UNIVERSITY OF TRADITI (CN) 2006-08-23 CN claimed
CN-1588007-A Polysaccharide quantitative detecting method and system SHANGHAI UNIV OF CHINESE MEDIC (CN) 2005-03-02 CN claimed
US-5723496-A ALZHEIMER'S DISEASE, ADMINISTERING AN ALKALINE SHIFTER COMPOUND OR A BUFFER, BASIFICATION THE REGENTS OF UNIVERSITY OF CALIFORNIA (US) 1998-03-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069290-A1 EJECTION LIQUID AND EJECTION METHOD GUCY1A1, NPPA, GUCY1A2 ALOX15 3365/4885SMN1; SMN2 880/4885MEN1 2343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.